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Abstract: Phenotropil [N-carbamoylmethyl-4-aryl-2-pyrrolidone (2-(2-oxo-4-phenyl-pyrrolidin-1-yl) acetamide; carphedon)] is
clinically used in its racemic form as a nootropic drug that improves physical condition and cognition. The aim of this study
was to compare the stereoselective pharmacological activity of R- and S-enantiomers of phenotropil in different behavioural
tests. Racemic phenotropil and its enantiomers were tested for locomotor, antidepressant and memory-improving activity and
influence on the central nervous system (CNS) using general pharmacological tests in mice. After a single administration, the
amount of compound in brain tissue extracts was determined using an ultra performance liquid chromatography–tandem
mass spectrometry (UPLC ⁄ MS ⁄ MS) method in a positive ion electrospray mode. In the open-field test, a significant increase
in locomotor activity was observed after a single administration of R-phenotropil at doses of 10 and 50 mg ⁄ kg and S-pheno-
tropil at a dose of 50 mg ⁄ kg. In the forced swim test, R-phenotropil induced an antidepressant effect at doses of 100 and
50 mg ⁄ kg, and S-phenotropil was active at a dose of 100 mg ⁄ kg. R-phenotropil significantly enhanced memory function in a
passive avoidance response test at a dose of 1 mg ⁄ kg; the S-enantiomer did not show any activity in this test. However, the
concentrations of R- and S-phenotropils in brain tissue were similar. In conclusion, the antidepressant and increased locomo-
tor activity relies on both R- and S-phenotropils, but the memory-improving activity is only characteristic of R-phenotropil.
These results may be important for the clinical use of optically pure isomers of phenotropil.
Phenotropil [N-carbamoylmethyl-4-aryl-2-pyrrolidone (2-(2-
oxo-4-phenyl-pyrrolidin-1-yl) acetamide; carphedon)] was
discovered in Russia several decades ago as a nootropic drug
that improves physical condition and cognition [1,2]. Ini-
tially, it was used on spaceships to increase the working
capacities of cosmonauts, but during the last 10 years, phe-
notropil has been introduced into clinical practice. The phe-
notropil molecule contains one chiral centre in the 4th
position of the pyrrolidone ring. Therefore, phenotropil can
exist in two forms that share an enantiomeric relationship.
The configuration of these two enantiomers has been desig-
nated the ‘R’ and ‘S’ forms (fig. 1A,B).
Phenotropil is a phenyl derivative of a known drug, pi-
racetam, which was the first representative of the nootropic
drugs [1,3]. Piracetam is used for treatment in patients with
mild to moderate dementia [4,5], cognitive impairment [6],
after-stroke rehabilitation [7,8] and alcohol-induced toxic
changes [9,10]. Also, phenotropil possesses nootropic drug-
like activity in different experimental and clinical set-ups [1].
After chronic administration to Wistar rats, racemic pheno-
tropil reduced the extent of neuralgic deficiency manifesta-
tions and retained the locomotor, research and memory
functions in gravitational cerebral ischaemia. Piracetam was
less effective compared with phenotropil [2]. Phenotropil also
exhibited antiepileptic action after metrazol-induced seizures
in mice [1] and significantly decreased the seizure and posi-
tive changes on the EEG in epileptic patients when used in
combination with antiepileptic drugs [11,12].
Although phenotropil could be separated into R- and
S-enantiomers, it is clinically used in the racemic form
(fig. 1A,B). Information concerning the comparative phar-
macological activity of R- and S-phenotropils is not avail-
able. Levetiracetam, an analogue of piracetam, is used in
clinical practice as an optically pure substance, and the anti-
convulsant action of levetiracetam is highly pronounced for
the S-enantiomer [13]. In the case of oxiracetam, which could
be separated into R- and S-enantiomers [14], a stereoselective
pharmacological activity has not been described. In the pres-
ent study, we explored the stereoselective pharmacological
activity of racemic phenotropil and its enantiomers in differ-
ent behavioural tests. We tested the effects of these com-
pounds using general central nervous system (CNS) tests, as
well as the locomotor, antidepressant and cognitive activity.
In addition, the amount of compound in brain tissue
extracts was determined after a single administration.
Materials and Methods
Chemicals. Racemic phenotropil and its optical isomers were pre-
pared at the Latvian Institute of Organic Synthesis according to a
previously published procedure [15]. Acetonitrile and methanol
(HPLC grade) were purchased from Merck (Darmstadt, Germany),
and 98% formic acid (LC ⁄ MS grade) was obtained from Fluka
(Buchs, Switzerland).
Author for correspondence: Liga Zvejniece, Latvian Institute of
Organic Synthesis Laboratory of Pharmaceutical Pharmacology,
Aizkraukles 21, Riga, LV-1006, Latvia (fax +371 67702405, e-mail
liga@biomed.lu.lv).
Basic & Clinical Pharmacology & Toxicology, 109, 407–412 Doi: 10.1111/j.1742-7843.2011.00742.x
 2011 The Authors
Basic & Clinical Pharmacology & Toxicology  2011 Nordic Pharmacological Society
Animals. Male ICR and CBA (antidepressant tests) mice (Labora-
tory Animal Breeding Facility, Riga Stradins University, Latvia)
weighing 23–25 g were housed under standard conditions (21–23C,
12-hr light ⁄ dark cycle) with unlimited access to standard food (Lac-
tamin AB, Mjçlby, Sweden) and water. All experimental procedures
were carried out in accordance with guidelines of the European
Communities Council Directive of 24 November 1986
(86 ⁄ 609 ⁄ EEC) and were approved by the Ethics Council of Animal
Protection at the Veterinary and Food Service, Riga, Latvia.
Open-field test. The test apparatus was an octagonal arena (36 cm
in diameter) with a black floor. The mice were gently placed in
the centre of the field, and behavioural parameters were recorded
using the EthoVision video tracking system (version 3.1.; Noldus,
Wageningen, The Netherlands). Distance moved (cm) and velocity
(cm ⁄ sec.) were recorded. Testing consisted of five successive 4-min.
sessions that started 30, 60, 120, 180 and 240 min. after the intraperi-
toneal (i.p.) administration of test drugs at doses of 5, 10 and
50 mg ⁄ kg in the volume of 10 ml ⁄ kg body-weight. The control
group received i.p. injection of saline.
Forced swim test. The forced swim test was performed as previously
described by Porsolt et al. [16] with a slight modification. The mice
were individually placed in a glass cylinder (26 cm high, 10 cm in
diameter), containing 19 cm of water maintained at 22–25C. The
total duration of immobility was recorded during the last 4 min. of
the 6-min. test period. The immobility time was recorded using the
EthoVision video tracking system (version 3.1.; Noldus). A mouse
was considered immobile whenever it floated passively in the water
and only made movements necessary to keep its head above the
water line. The animals received an i.p. injection of racemic and R-
and S-phenotropils at doses of 10, 50 and 100 mg ⁄ kg 30 min. prior
to experiment in the volume of 10 ml ⁄ kg body-weight. The control
group received i.p. injection of saline.
Passive avoidance response test. The passive avoidance response
(PAR) test was used as described previously [17]. A step-through
inhibitory avoidance apparatus (Ugo Basile, Comerio, Italy) con-
sisted of two compartments, a light compartment (10 · 18 · 17 cm)
and a dark compartment (10 · 18 · 17 cm). A sliding door opening
(4 · 4 cm) was positioned on the floor in the centre of the partition
between the two compartments. Stainless steel grids (2.5 mm in
diameter) were placed at 8-mm intervals (the distance between the
centres of the grids) on the floor of the dark compartment to pro-
duce a foot shock. Intermittent electric shocks were delivered to the
grid floor of the dark compartment by an insulated stimulator.
On the acquisition day (training), each mouse was individually
placed in the light compartment with no access to the dark compart-
ment and allowed to explore for 60 sec. When 60 sec. expired, the
sliding door was automatically opened and the mouse was allowed
to cross over into the dark compartment. Upon entering the dark
compartment, the mouse received a shock of 0.1 mA for 3 sec., the
door was closed and the mouse was returned to its home cage after
20 sec. The latency to enter the dark compartment was recorded.
Animals remaining in the light compartment for more than 100 sec.
during the training session received no shock and were excluded
from the retention test. The memory retention test was performed
on the next day without any shock. The mice were again positioned
in the illuminated compartment, and the time taken to enter the dark
compartment was recorded as the retention latency. A maximum
retention latency of 540 sec. was given to mice that did not enter the
dark compartment. The apparatus was cleaned after each trial.
The animals received an i.p. injection of racemic R- and S-pheno-
tropils at doses of 1 and 10 mg ⁄ kg 1 hr prior to acquisition trial in
the volume of 10 ml ⁄ kg body-weight. The control group received i.p.
injection of saline.
General central nervous system (CNS) tests. The effects of drugs
were evaluated before and 30, 60, 120 and 180 min. after an i.p.
administration at doses of 50, 100, 250 and 500 mg ⁄ kg in the volume
of 10 ml ⁄ kg of body-weight. A rota-rod test [18] was used to mea-
sure motor coordination (Model 7600; Ugo Basile). One day before
the experiment, the animals were trained on the apparatus, and the
animals that failed to remain on the rotating rod for at least 90 sec.
were excluded from further testing. On the experiment day, the ani-
mals were placed on a rota-rod (16 rpm), and the number of animals
falling off the rota-rod within the 180-sec. session was recorded.
The effect of drugs on motor performance was tested also in the
chimney test as described previously [19]. In this test, the mice had
to climb backwards up a Pyrex glass tube (30 cm length, 3 cm inner
diameter). Mice successfully reaching the 20 cm mark within 30 sec.
were selected for further testing.
The effect of drugs on muscle strength was examined in the trac-
tion test. Hence, the forepaws of a mouse were placed on a horizon-
tal firmly fixed stick. The untreated mice grasped the stick with both
forepaws and, when allowed to hang free, placed at least one hind
foot on the stick within 5 sec. Inability to perform that was scored
as a failure of traction. The rectal temperature of animals was mea-
sured using a thermometer (Thermalert TH-5; Physitemp, Clifton,
NJ, USA).
Determination of R- and S-phenotropils by UPLC ⁄ MS ⁄ MS. The
mice received an i.p. injection of R- and S-phenotropils at a dose of
100 mg ⁄ kg 30 min. before decapitation. The brain tissue was gently
removed and homogenized using a Cole Parmer 130-Watt ultrasonic
processor set at 20 kHz twice for 10 sec. each in ice-cold Milli-Q
water at w ⁄ v ratio 1:5. The obtained homogenate was centrifuged at
42,000 · g for 10 min. at 4C. The supernatant was then decanted
but the pellet was homogenized in the same volume of Milli-Q water
as before. The obtained homogenate was centrifuged at 42,000 · g
for 10 min. at 4C. The supernatants were combined and stored
frozen ()80C) until analysed.
The concentration of R- and S-phenotropils in brain tissue
extracts was determined using an ultra performance liquid chroma-
tography–tandem mass spectrometry (UPLC ⁄ MS ⁄ MS) method in a
positive ion electrospray mode. A sample preparation was performed
by deproteinization with an acetonitrile ⁄ formic acid mixture. Brain
tissue extract (100 ll) was mixed with 500 ll of 0.1% formic acid
solution in acetonitrile (v ⁄ v), vortexed and centrifuged at 9279 · g
for 20 min. One hundred microlitres of the supernatant was diluted
with 500 ll of a mobile phase solution (methanol ⁄ 0.1% formic acid,
70:30, v ⁄ v), transferred into UPLC vials and used for
UPLC ⁄ MS ⁄ MS analysis. Calibration was made with external cali-
bration standard solutions.
UPLC was carried out using the Waters Acquity UPLC system
equipped with the Acquity BEH Shield RP18 column (2.1 ·
100 mm, 1.7 lm). The injection volume was 5 ll. Chromatographic
separation was performed in a gradient elution mode from 70% to
90% methanol in the mobile phase (methanol and aqueous 0.1% for-
mic acid) at a flow rate of 0.15 ml ⁄ min. MS ⁄ MS analysis was per-
formed on a Micromass Quattro Micro tandem mass spectrometer
(Micromass, Manchester, UK) in positive ion mode using multiple
reaction monitoring of the transition from m ⁄ z 219.0 to 173.9 (cone









Fig. 1. Structures of R-phenotropil (A) and S-phenotropil (B).
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software with a QuanLynx 4.1. module (Waters Corporation, Mil-
ford, MA, USA) was used for data acquisition and processing.
Statistical analysis. All results are expressed as the mean € S.E.M.
The data were evaluated by a one-way, two-way or repeated-mea-
sures analysis of variance (ANOVA). Post hoc comparisons between
individual groups were made with Newman–Keuls test. The effective
dose 50 (ED50) values were obtained by probit analysis [20]. p-values
<0.05 were considered to be significant.
Results
Open-field test.
Locomotor activity was tested in an open-field test 30, 60,
120, 180 and 240 min. after a single i.p. administration of
racemic phenotropil and R- and S-enantiomers at doses of 5,
10 and 50 mg ⁄ kg (fig. 2A–D). To compare the efficacy of
racemic phenotropil and its optical isomers, the two-way
ANOVA was calculated. The significance was found for the
main effects of locomotor activity as represented by the
moved distance [effects of drug (F2,64 = 3.105; p < 0.05) and
dose (F2,64 = 3.243; p < 0.05), but no interaction between
drug and dose (F4,64 = 1.912; p > 0.05)] and velocity [effects
of dose (F2,64 = 4.382; p < 0.05), but no of drug (F2,64 =
2.219; p > 0.05) and interaction between drug and dose
(F4,64 = 2.02; p > 0.05)] (fig. 2A,C). ANOVA with repeated
measures showed that compounds induced a time-dependent
increase in locomotor activity as represented by the moved
distance [fig. 2B, main effect of time (F4,124 = 60.32;
p < 0.001) and drug (F3,124 = 20.63; p < 0.001), but no inter-
action (F12,124 = 0.994; p > 0.05)] and velocity (fig. 2D, main
effect of time (F4,124 = 65.43; p < 0.001) and drug (F3,124 =
14.38; p < 0.001), but no interaction (F12,124 = 1.419;
p > 0.05)] in the open-field test.
R-phenotropil induced significant changes in locomotor
activity as represented by the moved distance (F3,31 = 10.37;
p < 0.0001) and velocity (F3,31 = 10.74; p < 0.0001) com-
pared with saline-treated animals at all of the doses used (5,
10 and 50 mg ⁄ kg). Moreover, this action of R-phenotropil
was maintained at a higher dose of 50 mg ⁄ kg for as long as
240 min. (p < 0.0001) (fig. 2A–D).
The administration of racemic phenotropil resulted in a
somewhat lower activity than was observed for R-phenotro-
pil, but the effect of R- and racemic phenotropils was not
significantly different. Racemic phenotropil stimulated loco-
motor activity at doses of 10 and 50 mg ⁄ kg and was main-
tained for 180 min. after administration.
The S-enantiomer produced an increase in locomotor
activity (p < 0.05) only at a dose of 50 mg ⁄ kg. Moreover,
the action of S-phenotropil at a dose of 50 mg ⁄ kg was signif-
icantly lower than that of the R-enantiomer at the same dose
in the open-field test (F3,31 = 8.962; p < 0.001) (fig. 2A–D).
Forced swim test.
The antidepressant action of the compounds was tested in
the forced swim test 30 min. after a single i.p. administration
of racemic and R- and S-phenotropils at doses of 10, 50 and
100 mg ⁄ kg. The data presented in fig. 3 show that all of the
tested compounds exerted an antidepressant-like action com-
pared with the behaviour of saline-treated mice [two-way






































































5 10 50 5 10 50 5 10 50




































30 min 60 min 120 min 180 min 240 min
Saline Phenotropil R-phenotropil S-phenotropil
A B
C D
Fig. 2. Effects of racemic phenotropil, R- and S-phenotropils in the open-field test in mice. Compounds were administered at doses of 5, 10 and
50 mg ⁄ kg i.p. The mice were observed 30, 60, 120, 180 and 240 min. after injection. (A) Moved distance (cm ⁄ 4 min.) 60 min. after injection;
(B) moved distance (cm ⁄ 4 min.) at all observed time-points at a dose of 50 mg ⁄ kg; (C) velocity (cm ⁄ sec.) 60 min. after injection; (D) velocity
(cm ⁄ sec.) at all observed time-points at a dose of 50 mg ⁄ kg. Each column represents the mean € S.E.M. of 8–10 animals. *p > 0.05 versus
saline-treated group, #p > 0.05 versus the respective dose of R-phenotropil.
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dose (F2,81 = 82,47; p < 0.0001), significant interaction
between drug and dose (F4,81 = 10.19; p > 0.0001)]. For ani-
mals treated with R-phenotropil, a decreased immobility
time was observed in a dose-dependent manner compared
with the control group at doses of 50 and 100 mg ⁄ kg
(F2,27 = 52.99; p < 0.0001). At a dose of 100 mg ⁄ kg, R-phe-
notropil administration induced an 8-fold decrease in immo-
bility time compared with the saline control group
(21 € 12 sec. ⁄ 4 min. and 174 € 12 sec. ⁄ 4 min., respectively).
The effect of R-phenotropil was significantly better com-
pared with the effect of racemic and S-phenotropil at the
same dose (F2,27 = 39.13; p < 0.0001), with the immobility
times being five and six times longer (fig. 3), respectively.
Passive avoidance response test.
The influence of R-, S- and racemic phenotropils on reten-
tion latency was examined using the PAR test in mice
(fig. 4). Fig. 4 shows the action of the R-enantiomer, where
the retention latency was increased after R-phenotropil
administration at doses of 1 and 10 mg ⁄ kg by 195% and
185%, respectively, compared with the control group
(F2,54 = 2.312; p < 0.05); racemic phenotropil showed the
same action (fig. 4). The administration of S-phenotropil did
not influence the retention latency. Moreover, the retention
latency in S-enantiomer-treated mice at a dose of 1 mg ⁄ kg
differed significantly (p < 0.05) from the respective R-pheno-
tropil-treated group (fig. 4).
There were no differences between the saline, racemic phe-
notropil and its optical isomer groups in entering the dark
compartment during the acquisition trial (data not shown).
General CNS tests.
Only R-phenotropil exerted inhibitory activity on muscle
strength and coordination in the chimney, traction and rota-
rod tests. Pre-treatment with racemic or S-phenotropil did
not influence muscle strength and coordination at doses up
to 500 mg ⁄ kg (table 1). None of the compounds induced
any changes in rectal temperature in the dose ranges used
(table 1).
Determination of the brain tissue content of R- and
S-phenotropils by UPLC ⁄ MS ⁄ MS.
R- and S-phenotropils were measured in brain tissue homo-
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Fig. 3. Effects of racemic, R- and S-phenotropils in the forced swim
test. The compounds were administered i.p. 30 min. prior to the
experiment at doses of 10, 50 and 100 mg ⁄ kg. Each column repre-
sents the mean € S.E.M. of 10 animals. *p > 0.05 versus saline-trea-
































Fig. 4. Effects of racemic phenotropil, R- and S-phenotropils in the
PAR test in mice. The animals received an i.p. injection of racemic,
R- and S-phenotropils at doses of 1 and 10 mg ⁄ kg 1 hr prior to
acquisition trial. Each column represents the mean € S.E.M of nine
animals. *p < 0.05 versus saline-treated group. #p < 0.05 versus the
respective dose of R-phenotropil.
Table 1.





ED50 (mg ⁄ kg)
R-phenotropil
ED50 (mg ⁄ kg)
S-phenotropil
ED50 (mg ⁄ kg)
Chimney >500 258 € 25 >500
Traction >500 250 € 40 >500
Rota-rod >500 320 € 65 >500
Rectal temperature >500 >500 >500
Effects of racemic phenotropil and its optical isomers in the chimney,
traction, rota-rod tests and rectal temperature. Compounds were
administered i.p. at doses of 50, 100, 250 and 500 mg ⁄ kg. The effects
were observed 30, 60, 120 and 180 min. after drug administration.






























Fig. 5. The amount of R- and S-phenotropils (lg ⁄ g) in mice brain
tissue. Mice received an i.p. injection of R- and S-phenotropils at a
dose of 100 mg ⁄ kg 30 min. prior to tissue collection. The amount of
compound in brain tissue extracts was measured using the ultra per-
formance liquid chromatography–tandem mass spectrometry method
in a positive ion electrospray mode. Each column represents the
mean € S.E.M. of seven mice.
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both compounds was similar: 73 € 7 lg ⁄ g for R-phenotropil
and 67 € 3 lg ⁄ g brain tissue for S-phenotropil. The concen-
tration of compounds in brain tissue 30 min. after i.p. injec-
tion at a dose of 100 mg ⁄ kg was about 1% of administered
amount (fig. 5).
Discussion
The results of the present study provide evidence that R-phe-
notropil is the most active enantiomer of phenotropil. After
a single administration, it increased locomotor and antide-
pressant activity in the open-field and forced swimming tests,
respectively, as well as enhanced memory in the PAR test.
Racemic phenotropil and S-phenotropil also stimulated loco-
motor activity and induced some antidepressant effect after
acute administration. However, S-phenotropil did not exert
any activity in the PAR test, although the amount of the
enantiomers in brain tissue was similar as shown by
UPLC ⁄ MS ⁄ MS.
Because phenotropil is structurally related to piracetam, a
known nootropic drug that increases physical capacity and
cognition processes [3,4,6], we tested the pharmacological
activity of racemic phenotropil and its enantiomers in experi-
mental set-ups related to those activities. In the PAR test, a
memory-improving activity was demonstrated by R- and
racemic phenotropils. S-phenotropil did not exert any activ-
ity to improve cognition in the PAR test (fig. 4). Therefore,
the presence of S-phenotropil in racemic phenotropil diluted
or suppressed its pharmacological activity in the PAR test.
We also measured the influence of the enantiomers of phe-
notropil on locomotor activity in the open-field test and used
the forced swimming test to determine the effect of the drug
on depressive state. In all cases, R-phenotropil was the most
active substance. At the same time, the racemic and S-pheno-
tropils showed some activity after acute administration.
In the forced swimming test, both racemic phenotropil and
S-phenotropil showed antidepressant activity at a dose of
100 mg ⁄ kg, but a dose of 50 mg ⁄ kg did not influence immo-
bility time compared with the control group (fig. 3). In the
open-field test, racemic phenotropil increased locomotor
activity at doses of 10 and 50 mg ⁄ kg, but S-phenotropil was
active at a dose of only 50 mg ⁄ kg (fig. 2A–D). Considering
that all compounds exerted significant effects in the open-
field test at five times lower doses than in the forced swim-
ming test, it could not be excluded that the decreased immo-
bility time in the forced swimming test might result from the
drug-induced increase in locomotor activity. In the general
CNS tests, R-phenotropil affected motor coordination and
muscle strength (ED50 250–320 mg ⁄ kg) as shown by the
rota-rod, chimney and traction tests. However, racemic and
S-phenotropils did not influence motor function at doses up
to 500 mg ⁄ kg (table 1). Moreover, the bioavailability of both
compounds in brain tissue after acute administration was
similar (fig. 5).
It can be suggested that the enantiomers of phenotropil
might have different affinities for the possible drug target or
that different targets could be involved in the pharmacologi-
cal activity of R- and S-phenotropils. Previously, it was
found that racemic phenotropil in vitro binds to nicotinic
acetylcholine receptors with an IC50 of 5.86 lM ⁄ l [21]. In an
ex vivo experiment in rats, a 7-day treatment with racemic
phenotropil at a dose of 100 mg ⁄ kg significantly increased
the Bmax of N-methyl-D-aspartate and nicotinic acetylcholine
receptors [21]. It has been shown in clinical settings and
experimental models that nicotinic acetylcholine and N-
methyl-D-aspartate receptors are involved in the modulation
of cognition and memory processes [22,23]. This is in agree-
ment with the results of the present study where a treatment
of R-phenotropil improved the response time in the PAR
test. The possible target receptors and mechanisms for the
acute activity of phenotropil remain unclear. Racemic pheno-
tropil does not bind to dopamine (D1, D2 and D3) or sero-
tonin (HT2) receptors [21]. In conclusion, using different
behavioural tests in mice, we have shown that the antidepres-
sant and increased locomotor activity of racemic phenotropil
relies on both enantiomers and is more pronounced of
R-phenotropil. Moreover, the memory-improving activity
was only characteristic of R-phenotropil. This may be
important for the clinical use of the optically pure isomers of
phenotropil.
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